Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Alan Bateson"'
Autor:
Nikos L. D. Chatzisarantis, Mark N. Harris, John Windus, Chris Twomey, Alan Bateson, Sviatlana Kamarova, Martin S. Hagger, Graham Hansen
Publikováno v:
European Journal of Health Psychology. 28:1-12
Abstract. Background: Previous research has documented that unemployed individuals who engage in recreational activities, either alone or with others, experience higher levels of mental health and psychological well-being relative to those who do not
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ccd1880c9e15fb19a53a2c75f1ac05c
https://doi.org/10.1027/2512-8442/a000058
https://doi.org/10.1027/2512-8442/a000058
Autor:
Alan Bateson, H. Valerie Curran, David S. Baldwin, David J. Nutt, Brian E. Leonard, David N. Stephens, Sue Wilson, Simon J. C. Davies, Katherine J. Aitchison
Publikováno v:
Journal of Psychopharmacology. 27:967-971
Over the last decade there have been further developments in our knowledge of the risks and benefits of benzodiazepines, and of the risks and benefits of alternatives to benzodiazepines. Representatives drawn from the Psychopharmacology Special Inter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5abe37874c08a5216e9107d061018f6
https://doi.org/10.1177/0269881113503509
https://doi.org/10.1177/0269881113503509
The manipulation of gene sequences between cells is a fundamental technique in genetics. Mammalian cells will take up and express genes when they are exposed to either metaphase chromosomes or naked genomic or recombinant DNA. In each case the uptake
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed13a4b0f268a877a8e8e50d420857f1
https://doi.org/10.1385/0-89603-064-4:321
https://doi.org/10.1385/0-89603-064-4:321
Autor:
Alan, Bateson
Publikováno v:
Current opinion in investigational drugs (London, England : 2000). 4(1)
Pagoclone is a cyclopyrrolone GABAA receptor modulator under development by Indevus for the potential treatment of panic and anxiety disorders. Indevus initiated phase II/III trials in November 1996. Pfizer had initiated a phase III trial for panic d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5e68952131b1e9e6d41fde33c1cb38dc
https://pubmed.ncbi.nlm.nih.gov/12625036
https://pubmed.ncbi.nlm.nih.gov/12625036